{"id":"antibiotic-of-investigator-s-choice","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL404986","moleculeType":"Small molecule","molecularWeight":"1589.59"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As an investigator's choice antibiotic in phase 3 development by Achaogen, the drug likely represents a novel or semi-synthetic antibiotic targeting bacterial ribosomes or cell wall synthesis. Achaogen's pipeline has historically focused on novel antibiotics for serious gram-negative infections, particularly those resistant to standard therapies.","oneSentence":"This antibiotic inhibits bacterial protein synthesis by binding to the bacterial ribosome.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:51.313Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-negative bacterial infections (investigator's choice indication)"}]},"trialDetails":[{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT02599493","phase":"PHASE4","title":"EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2016-01","conditions":"Osteoarticular Infection","enrollment":544},{"nctId":"NCT01098266","phase":"PHASE3","title":"NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed","status":"COMPLETED","sponsor":"AGC Biologics S.p.A.","startDate":"2010-04-12","conditions":"Malignant Pleural Mesothelioma","enrollment":400},{"nctId":"NCT02083653","phase":"PHASE2","title":"Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Symphogen A/S","startDate":"2014-03-06","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT01970371","phase":"PHASE3","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2014-09-16","conditions":"Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE","enrollment":69},{"nctId":"NCT01104662","phase":"PHASE4","title":"Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-04-19","conditions":"Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment","enrollment":92},{"nctId":"NCT00488345","phase":"PHASE2","title":"Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-12","conditions":"Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"antibiotic of Investigator's choice","genericName":"antibiotic of Investigator's choice","companyName":"Achaogen, Inc.","companyId":"achaogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This antibiotic inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Serious gram-negative bacterial infections (investigator's choice indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}